246 results about "False proteinuria" patented technology

Systemic suppression of the complement system has been shown to be effective to treat inflammatory disease, yet at the potential cost of compromising host defense and immune homeostasis. Herein disclosed are methods for antigen-specific targeting of complement inhibitors that show that complement inhibitors targeted to the proximal tubular epithelium protect against tubulointerstitial injury and renal dysfunction in a rat model of nephrosis. It is shown that appropriate targeting of a systemically administered complement inhibitor to a site of disease markedy enhances efficacy and obviates the need to systemically inhibit complement. Additionally, it is shown by specifically inhibiting the terminal pathway of complement, that the membrane attack complex (MAC) plays a key role in proteinuria-induced tubulointerstitial injury, thus establishing the MAC as a valid target for pharmacological intervention in proteinuric disorders. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

Methods are provided for preventing or treating risk factors for cardiovascular disease in an individual, comprising administering a therapeutically effective amount of a composition comprising an estradiol metabolite to said individual. Such risk factors include obesity, the metabolic syndrome, diabetes mellitus, vascular disorders, and renal disorders. Preferred estradiol metabolites include 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol, and 4-hydroxyestradiol or prodrugs thereof. The compositions may also be in the form of a controlled release formulation. Methods are also provided for use of estradiol metabolites to treat or prevent insulin resistance, vascular endothelial dysfunction, hyperlipidemia, hypertension, diabetic nephropathy, proteinuria and reducing leptin levels. In addition, the methods provide a method of stabilizing glucose levels. These treatments may be used in either gender because of their lack of a feminizing estrogenic effect.

This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.

In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and / or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

The invention discloses a single-chain antibody of human source anti-alexin C3d molecules. A light chain and a heavy chain of the antibody have a unique CDR region; excellent antigen binding activityis realized; the affinity constant reaches 1.22*10<-7> mol / L. Biological distribution experiments prove that the anti-C3d single-chain antibody provided by the invention can be highly gathered in thearthritis positions after entering a mouse model with rheumatoid arthritis; the arthritis serious degree of the three ScFv treatment groups is obviously lower than that of a PBS group; the healing degree has the obvious dose dependency relationship; the result shows that the excellent anti-adhesion / anti-inflammatory targeted inhibition effects are achieved. In the treatment process on MRL / lpr mice with lupus erythematosus, the anti-C3d single-chain antibody provided by the invention can obviously improve the survival rate of the mice; the symptoms of proteinuria, glomerular score, interstitial inflammation, vasculitis and crescent / necrosis and the like in the treatment group are obviously relieved. The result shows that the anti C3d single-chain antibody provided by the invention has excellent application prospects in the preparation of medicine for treating autoimmune diseases.

The present invention relates to a compound of Antrodia camphorata used to treat autoimmune diseases, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone, isolated from Antrodia camphorata, and its use in alleviating symptoms of autoimmune diseases such as systemic lupus erythematosus (SLE). The cyclohexenone compound according to the present invention helps to decrease proteinuria levels and antinuclear antibody titers in SLE mammals in order to alleviate kidney inflammation and disease, as well as the self-damage caused by antinuclear antibodies. The purpose for prevention and treatment of autoimmune diseases and kidney diseases by the natural, side-effect free substance can then be accomplished.

A support vector machine (110) is used to predict who, among a population of patients with diabetes mellitus, will develop proteinuria which is in indicator of diabetic nephropathy. The support vector machine (110) is trained using test results of the patients from blood biochemistry and haemotology tests. The training and testing of the support vector machine (110) used data in which the entire patient population did not exhibit signs of proteinuria at a predetermined time period and three months later, and some of the patient population had proteinuria six months from the predetermined time period. The support vector machine (110) is used to predict who, among patients with diabetes mellitus using lest results from a predetermined time period and three months later, will develop proteinuria at six months from the predetermined time period. The input data to the support vector machine (110) included different parameters of test results at a predetermined time and three months later.

The invention relates to novel methods of using 2-methylene-19-nor-20(S)-1,25-dihydroxyvitamin D3 to prevent renal disease, particularly Lupus nephritis, in a subject at risk of developing renal disease. Methods of preventing symptoms of renal disease, such as proteinuria, splenomegaly or glomerular damage are also provided. Methods of treating symptoms of renal disease, including proteinuria and splenomegaly, are also provided.

The invention relates a pharmaceutical composition comprising a combination of:(i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof; and(ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or diseaseselected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction, such as Alzheimer's, glaucoma and stroke, comprising administering a therapeutically effective amount of the pharmaceutical composition to a mammal in need thereof.

Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to ameliorate renal failure (e.g., improved diuretic effect and / or lowering blood urea nitrogen, proteinuria, and / or serum creatinine levels) in a subject as a result of having been cultured in the presence of an alternating electric field having a specific frequency and a specific field strength. Also included are methods of making and using such compositions.

A composition including an aliquot of the herb Herba Epimedii; and an aliquot of at least three supplemental herbs selected from the group consisting of Fructus Rosae Laevigatae; Fructus Rubi; Fructus Psoralea; Radix Morindae Officinalis; Fructus Schisandrac Chinensis; Fructus Ligustri Lucidi; Semen Cuscutae; and Radix Astragali. A composition including icariin; ursolic acid; ellagic acid; psoralen; deoxyschizandrin; oleanolic acid; quercetin; aslvagaloside; and an extract of the herb Radix Morindae Officinalis. Methods including administering a composition directed at treatment of various kidney disorders or the promotion of kidney health and to the overall health of the kidney, including the use of a composition in the treatment of prostate cancer, prophylatic prostate health, reduction of polyuria, incontinence, proteinuria, as well as for sexual satisfaction.

The invention discloses a composite kidney-benefiting medicine and belongs to Chinese herbal composite medicine. The composite kidney-benefiting medicine comprises astragalus, angelica sinensis, red peony root, rhizoma chuanxiong, glossy privet fruit, eclipta, lalang grass rhizome, moutan bark, fructus kochiae and glycyrrhiza. The composite kidney-benefiting medicine can effectively cure pure simple hematuresis and hematuresis proteinuria, comprises immune globulin A (IgA) nephropathy, anaphylatic purpura nephritis, nephrotic syndrome, comprises nephritis type with hematuresis, can confront side effect of nephrotic syndrome which is cured by hormone, can play roles in promoting blood circulation to remove blood stasis and preventing and curing hypercoagulable state and has the advantages of being prominent in curative effect, convenient to take and good in taste.

A composition including an aliquot of the herb Herba Epimedii; and an aliquot of at least three supplemental herbs selected from the group consisting of Fructus Rosae Laevigatae; Fructus Rubi; Fructus Psoralea; Radix Morindae Officinalis; Fructus Schisandrac Chinensis; Fructus Ligustri Lucidi; Semen Cuscutae; and Radix Astragali. A composition including icariin; ursolic acid; ellagic acid; psoralen; deoxyschizandrin; oleanolic acid; quercetin; aslvagaloside; and an extract of the herb Radix Morindae Officinalis. Methods including administering a composition directed at treatment of various kidney disorders or the promotion of kidney health and to the overall health of the kidney, including the use of a composition in the treatment of prostate cancer, prophylatic prostate health, reduction of polyuria, incontinence, proteinuria, as well as for sexual satisfaction.

The invention discloses a traditional Chinese medicine composition for treating chronic nephritis proteinuria, and the traditional Chinese medicine composition is mainly prepared by the following active pharmaceutical ingredients in parts by weight: 20-50 parts of raw membranous milkvetch root, 15-30 parts of pilose Asiabell root, 15-30 parts of Chinese peashrub root, 15-30 parts of raw coix seedroot, 18-30 parts of fructus forsythiae, 12-30 parts of honeysuckle flower, 18-30 parts of heartleaf houttuynia herb, 15-30 parts of spreading hedyotis herb, 9-20 parts of Szechuan lovage rhizome, 9-20 parts of tree peony bark, 15-30 parts of motherwort herb, 15-30 parts of Indian buead, 15-30 parts of corn silk and 15-30 parts of winged euonymus twig. In addition, the invention further disclosesa preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition can combine tonification with purgation, perform warming and cooling simultaneously,effectively eliminate the proteinuria and other pathological indicators of kidneys, delay and even block the progress of chronic nephritis and realize the significant protection effect for the kidneys.

In one aspect, the invention provides methods for reducing proteinuria in a human subject suffering, or at risk of developing Immunoglobulin A Nephropathy (IgAN). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2-dependent complement activation.

The invention relates to a rosuvastatin calcium sustained-release preparation and a preparation method thereof. The rosuvastatin calcium sustained-release preparation basically contains 5 to 10mg of rosuvastatin calcium, and the balance of sustained-release framework material and other pharmaceutical excipients. The preparation method is simple; and all the materials are proportioned and the preparation is prepared by the preparation method for common tablets, granules or capsules. The rosuvastatin calcium sustained-release preparation prepared by the method avoids adverse reactions such as rhabdomyolysis, proteinuria, nephrosis, kidney failure, hepatotoxicity and the like caused by overdosage of medicaments; meanwhile, due blood concentration and time for treating diseases after the medicaments are taken can be maintained, and the peak valley phenomenon of the blood concentration is effectively avoided.

The invention relates to methods, compositions, and kits for the treatment of proteinuria and / or hypertension (e.g., proteinuria and / or hypertension arising from primary renal disease (e.g., focal segmental glomerulosclerosis, glomerular disease) or secondary to other conditions (e.g., diabetes, diabetic nephropathy, liver disease). Specifically, the invention relates to methods involving combination therapy wherein an indoline (e.g., indapamide) is administered in combination with an anti-aldosterone agent (e.g., spironolactone and / or epleronone).

Methods of treating lupus, including systemic lupus erythematosus, cutaneous lupus erythmetosus, and lupus nephritis, are provided. The methods involve administration of a combination of a non-depleting CD4 antibody and another compound used clinically or experimentally to treat lupus. Methods of treating lupus nephritis by administration of a non-depleting CD4 antibody that results in an improvement in renal function and / or a reduction in proteinuria or active urinary sediment are also provided. Methods of treating multiple sclerosis by administration of a non-depleting CD4 antibody, optionally in combination with another compound used clinically or experimentally to treat MS, are described. Methods of treating transplant recipients and subjects with rheumatoid arthritis, asthma, psoriasis, Crohn's disease, ulcerative colitis, and Sjogren's syndrome are also provided.

The invention discloses a novel low-toxicity tripterygium polyglycoside. The novel low-toxicity tripterygium polyglycoside is obtained via chemical processing and adding of triptolide. The invention also discloses applications of the novel low-toxicity tripterygium polyglycoside in the field of medicine. The novel low-toxicity tripterygium polyglycoside is capable of relieving nephrotic syndromes such as kidney pathological injury and proteinuria, improving body inflammation level, possesses obvious curative effect on nephrotic syndromes, is low in toxicity, and effect lasts long.

The invention discloses a traditional Chinese medicine preparation for treating chronic kidney disease proteinuria, which comprises the following raw materials in parts by weight: 15-30 parts of codonopsis pilosula, 6-15 parts of radix asparagi, 10-15 parts of prepared rehmannia root, 5-10 parts of bark of Chinese corktree, 10-15 parts of rehmannia root, 3-5 parts of villous amomum fruit and 3-10parts of licorice root. The preparation method comprises the steps of decocting the raw materials in water according to required proportions first, carrying out reduced-pressure concentration after filtering, then adding adjuvants, and carrying out granulating and drying. The traditional Chinese medicine preparation not only has an obvious curative effect on kidney yin deficiency syndrome, but also can effectively relieve the symptom of hyperactivity of fire due to yin deficiency.

The present disclosure provides a biochemical basis of nephrotic syndrome and provides and explanation for the observed proteinuria and other effects. As a result, the present disclosure provides method for treating and / or preventing nephrotic syndrome as well as methods of alleviating symptoms associated with nephrotic syndrome. The present disclosure further provides methods for reducing proteinuria in nephrotic syndrome and other disease states as discussed herein.

The invention relates to the technical field of medicine, in particular to a new application of scutellarin, and provides the application of the scutellarin in preparing medicine for reducing pathological changes of kidney tissue and the application of the scutellarin in preparing medicine for treating nephritis. The new application of the scutellarin is proved by experiments to show that the intragastric administration is continuously performed on nephritis model rats with the scutellarin in the dose of 20 mg / kg and 40 mg / kg for eight weeks, the proteinuria of the model animals can be obviously reduced, hypoproteinemia, hyperlipidemia and the hypercoagulable state of blood can be corrected, the serum lipid peroxidation product content of the model rats can be lowered, the expression of TNF-alpha in the kidney tissue can be inhibited, and a protection effect on the kidney tissue and a good improvement effect on the kidney function are achieved; in addition, the maximum dose of intragastric administration on the rats is equal to and more than 18 g / kg, and obvious acute toxicity reaction and death do not occur on the animals.

The invention discloses a short peptide, a preparation method thereof, and applications of the short pepetide in diagnosis or treatment of apoA-I related diseases. The sequence of the short peptide is Ac-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH2, wherein the amino acids used are all L-amino acids. An L-4F provided by the invention has functions similar to the apoA-I. In an accelerated arteriosclerotic mice lupus model, the L-4F is capable of reducing significantly double-stranded DNA resistance and oxidized-type PL resistance of IgG, improving degrees of proteinuria, glomerulonephritis and sclerotin reduction, increasing the amount of smooth muscle cells, reducing infiltration of macrophages, and reducing the level of inflammation chemotactic factors causing atherosclerosis at the same time. Accordingly, the L-4F treatment is a protective mechanism for lupus diseases, also has certain functions for rebuilding and fixing latent patches, and has a broad application prospect and high application value. The L-4F can be used for diagnosis and treatment of the apoA-I related diseases, and has high medicinal value. The L-4F is obtained by a solid-phase synthetic method with simple operation, and therefore the L-4F has a broad market prospect.

Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+,K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.

The invention provides a screening method for proteinuria component induced renal interstitial fibrosis based on a micro-fluidic chip. The micro-fluidic chip comprises twelve identical structure units. The structure units are connected through central pools. Each structure unit is composed of a stimulant inlet pool (1), a fluid buffer channel (2), a cell culture pool (3) and a central pool (4). The screening method for the proteinuria component induced renal interstitial fibrosis based on the micro-fluidic chip integrates chip cell culture, cell and factor interaction, fluid stimulation, cell marking and cell responding signal detection on the chip of several square centimeters, and can be used for analyzing a proteinuria component induced renal interstitial fibrosis mechanism. Compared with a perforated plate technology, the screening method for the proteinuria component induced renal interstitial fibrosis based on the micro-fluidic chip saves the cumbersome step of repeated cell inoculation, solves the problems that different factors cannot act on cells at the same time under the flow condition, reduces the consumption of the cells and reagent, and can achieve a plurality of experiment parameters through one-time operation.

The invention discloses a traditional Chinese medicine compound combination with a function of curing chronic kidney diseases. The traditional Chinese medicine compound combination is prepared by 20-60 parts of astragali radix, 15-45 parts of eucommia ulmoides, 10-30 parts of glossy privet fruit, 10-30 parts of cherokee rose fruit, 30-90 parts of caulis sinomenii, 30-90 parts of herba pyrrosiae, 15-45 parts of radix ranunculi ternati, 20-60 parts of rhizoma dioscoreae nipponicae, 15-45 parts of stiff silkworms and 5-15 parts of scorpion. The invention further discloses a preparation method of the traditional Chinese medicine compound combination and an application of the traditional Chinese medicine compound combination in curing the curing chronic kidney diseases. The traditional Chinese medicine compound combination is obtained through long-time clinical application and screening under the guidance of the traditional Chinese medicine theory according to the pathogenesis of the chronic kidney diseases. Clinical test results show that the traditional Chinese medicine compound combination can remarkably reduce proteinuria, protect the kidney function and control and stabilize the illness condition of a patient suffering from chronic nephritis, the effective rate is up to 91.7%, no remarkable adverse reaction occurs in the test process, the application is safe, and the traditional Chinese medicine compound combination is hopeful to be developed into a new drug for curing proteinuria of chronic nephritis.

The invention aims to disclose a fermented broad bean with a health care effect and a preparation method of the fermented broad bean with the health care effect. The fermented broad bean with the health care effect comprises the following materials: 60-70 parts of broad beans, 12-15 parts of lotus seeds, 5-7 parts of pollen pini, 4-6 parts of astragalus membranaceus, 4-6 parts of eleusine indica, 1.6-2 parts of cowpea leaves, 1-1.4 parts of Chinese hawthorn seeds, 0.6-1 part of rhodiola rosea, 2-3 parts of Sichuan pepper, 8-12 parts of salad oil, 9-13 parts of millet wine, 12-18 parts of salt, and 8-10 parts of garlic. The produced fermented broad bean with the health care effect is delicious and special in fragrant flavor. The added astragalus membranaceus has the effects of tonifying qi and strengthening exterior, arresting sweating and relieving depletion, supporting sore muscles, and inducing diuresis to alleviate edema, and has a certain effect of deficiency of vital energy and lacking in strength, sinking of middle qi, chronic diarrhea and rectocele, hemafecia metrorrhagia and metrostaxis, exterior deficiency and spontaneous perspiration, ulcer difficult to collapse, long collapse without restraining, deficiency of blood and chlorosis, internal thermal diabetes, chronic nephritis, proteinuria, and diabetes mellitus. Alkaloid in the lotus seeds has a remarkable heart strengthening effect, and lotus seed alkali has strong calcium resistant and arrhythmia resistant effects. Products of the fermented broad bean with the health care effect further comprise Chinese herbal medicinal ingredients beneficial to human bodies, and long-term consumption is beneficial to the human bodies.